Toll Free: 1-888-928-9744

Liposarcoma - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liposarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma - Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape.

Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liposarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liposarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liposarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 3 and 2 respectively.Liposarcoma.

Liposarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liposarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Liposarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liposarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liposarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Liposarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liposarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liposarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Liposarcoma Overview 7 Therapeutics Development 8 Pipeline Products for Liposarcoma - Overview 8 Liposarcoma - Therapeutics under Development by Companies 9 Liposarcoma - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Liposarcoma - Products under Development by Companies 13 Liposarcoma - Companies Involved in Therapeutics Development 14 Adaptimmune Therapeutics Plc 14 Amgen Inc 15 Cellceutix Corp 16 Eli Lilly and Company 17 Horizon Pharma Plc 18 Immune Design Corp 19 Karyopharm Therapeutics Inc 20 Merck & Co Inc 21 Mirati Therapeutics Inc 22 Novartis AG 23 Pfizer Inc 24 Liposarcoma - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 29 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 abemaciclib - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AMG-232 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 CMB-305 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 everolimus - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 GSK-3377794 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 HDM-201 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 interferon gamma-1b - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Kevetrin - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 palbociclib - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 pazopanib hydrochloride - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 pembrolizumab - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 ribociclib succinate - Drug Profile 130 Product Description 130 Mechanism Of Action 130 R&D Progress 130 selinexor - Drug Profile 135 Product Description 135 Mechanism Of Action 135 R&D Progress 135 sirolimus - Drug Profile 152 Product Description 152 Mechanism Of Action 152 R&D Progress 152 sitravatinib - Drug Profile 153 Product Description 153 Mechanism Of Action 153 R&D Progress 153 Vimo-101 - Drug Profile 156 Product Description 156 Mechanism Of Action 156 R&D Progress 156 Liposarcoma - Dormant Projects 157 Liposarcoma - Discontinued Products 158 Liposarcoma - Product Development Milestones 159 Featured News & Press Releases 159 Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma 159 Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159 Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159 Appendix 161 Methodology 161 Coverage 161 Secondary Research 161 Primary Research 161 Expert Panel Validation 161 Contact Us 161 Disclaimer 162
List of Tables
Number of Products under Development for Liposarcoma, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 14 Liposarcoma - Pipeline by Amgen Inc, H2 2016 15 Liposarcoma - Pipeline by Cellceutix Corp, H2 2016 16 Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016 17 Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016 18 Liposarcoma - Pipeline by Immune Design Corp, H2 2016 19 Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 20 Liposarcoma - Pipeline by Merck & Co Inc, H2 2016 21 Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016 22 Liposarcoma - Pipeline by Novartis AG, H2 2016 23 Liposarcoma - Pipeline by Pfizer Inc, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 30 Number of Products by Stage and Route of Administration, H2 2016 33 Number of Products by Stage and Molecule Type, H2 2016 35 Liposarcoma - Dormant Projects, H2 2016 157 Liposarcoma - Discontinued Products, H2 2016 158



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify